AVIR:NSD-Atea Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.25

Change

+0.11 (+1.54)%

Market Cap

USD 0.61B

Volume

0.94M

Avg Analyst Target

USD 9.33 (+28.74%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Atea Pharmaceuticals Inc (AVIR) Stock Analysis:
Based on the Atea Pharmaceuticals Inc stock forecasts from 3 analysts, the average analyst target price for Atea Pharmaceuticals Inc is USD 9.33 over the next 12 months. Atea Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Atea Pharmaceuticals Inc is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, Atea Pharmaceuticals Inc’s stock price was USD 7.25. Atea Pharmaceuticals Inc’s stock price has changed by +12.75% over the past week, +13.64% over the past month and -66.99% over the last year.

About

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.05 (-0.31%)

USD71.36B 9.16 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+3.10 (+1.23%)

USD64.54B 26.63 18.23
MRNA Moderna Inc

+5.67 (+4.12%)

USD54.78B 4.05 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+10.81 (+6.88%)

USD36.74B 3.67 1.75
SGEN Seagen Inc

-0.37 (-0.26%)

USD26.32B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.84 (+2.84%)

USD19.31B 46.16 5.06
ARGX argenx SE

+15.26 (+5.01%)

USD17.59B N/A N/A
INCY Incyte Corporation

+0.95 (+1.29%)

USD16.26B 17.19 22.08

ETFs Containing AVIR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.90% 81% B- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.90% 81% B- 52% F
Trailing 12 Months  
Capital Gain -68.98% 44% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.98% 44% F 20% F
Trailing 5 Years  
Capital Gain 1,329.98% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,329.98% 96% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain -2.61% 43% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.61% 42% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 40.39% 69% D+ 37% F
Risk Adjusted Return -6.47% 42% F 33% F
Market Capitalization 0.61B 79% C+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.39 53% F 83% B
Price/Book Ratio 0.85 73% C 81% B-
Price / Cash Flow Ratio -7.06 74% C 73% C
EV/EBITDA 3.58 24% F 75% C
Management Effectiveness  
Return on Equity 19.27% 96% A 84% B
Return on Invested Capital 19.24% 93% A 87% B+
Return on Assets 10.57% 97% A+ 93% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.80 60% D- 43% F
Short Percent 3.11% 64% D 49% F
Beta -0.61 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.